Sermorelin for Pediatric Growth Hormone Deficiency: What Clinicians Actually Do

What Sermorelin Actually Is, and Why Its FDA Status Is Complicated

Sermorelin is a 29-amino-acid synthetic analog of endogenous growth hormone-releasing hormone (GHRH). It tells the pituitary gland to produce and secrete growth hormone on its own. That is a fundamentally different mechanism from recombinant human growth hormone (rhGH), which bypasses the pituitary entirely and delivers synthetic GH directly.

Geref (sermorelin acetate) received FDA approval in 1997 specifically for the treatment of idiopathic growth hormone deficiency in children. In 2008, Serono withdrew Geref from the U.S. Market. The withdrawal was a business decision tied to cost and market competition, not a safety signal. No efficacy or safety problems drove the withdrawal.

Because no branded product remains on the market, sermorelin prescribed for pediatric GHD today comes almost exclusively from FDA-registered 503A or 503B compounding pharmacies. That means variable quality assurance, no standardized dosage form, and prescribing that is explicitly off-label. Clinicians who use it for children are making a reasoned clinical decision, not following a current package insert.

Why Some Clinicians Still Choose Sermorelin Over rhGH

The primary driver is cost. Branded rhGH products such as Norditropin, Genotropin, and Humatrope can cost $10,000 to $60,000 per year depending on dose and payer. Compounded sermorelin runs significantly less, sometimes 50 to 80 percent of the cost of rhGH, though exact pricing varies by pharmacy and region.

A second rationale is physiologic appeal. Because sermorelin works through the pituitary's own feedback loop, it preserves the normal pulsatile pattern of GH secretion. Endogenous GH release is not suppressed the way it can be with exogenous rhGH. Some clinicians argue this reduces the risk of tachyphylaxis or receptor downregulation, though long-term head-to-head data comparing sermorelin with modern rhGH in children is limited. That evidence gap is real and worth naming.

The Evidence Base: What Is Directly Studied vs. Extrapolated

The landmark sermorelin trial in children was Ross et al. (1987), which demonstrated that GHRH(1-29) stimulated growth velocity in GH-deficient children. Later studies through the 1990s confirmed growth velocity increases in the range of 3 to 5 cm per year above pretreatment rates in responders. However, most of these trials enrolled mixed-sex populations with small female subgroups. Sex-stratified outcomes for girls specifically are rarely reported. Clinicians prescribing sermorelin to girls today are extrapolating from data that is mostly male-predominant. That is an honest limitation you deserve to know.

How Sermorelin Works Differently in Girls

Growth hormone physiology in females is not identical to males. This matters for dosing, response, and treatment windows.

The Role of Estrogen in GH Secretion

Estrogen is a potent stimulator of GH pulse amplitude. During puberty, rising estradiol levels increase GH secretion from the pituitary. This means a pubertal girl already has higher endogenous GH pulsatility than a prepubertal child or an adult woman. Research published in the Journal of Clinical Endocrinology and Metabolism showed that estrogen replacement in GH-deficient women significantly increased GH secretion, confirming the estrogen-GH axis is a real and clinically relevant interaction.

For girls with GHD who are starting puberty, this estrogen-priming effect means the pituitary may respond more briskly to sermorelin than in prepubertal children. Some clinicians adjust expectations accordingly and may see better response during early puberty than before it.

Bone Age and the Closing Treatment Window

Girls fuse their growth plates earlier than boys. The average age of epiphyseal fusion in girls is 14 to 16 years; in boys it is closer to 16 to 18 years. Once growth plates close, no amount of sermorelin or rhGH will add height. This creates a narrower treatment window for girls with late-diagnosed GHD.

Growth Hormone Research Society (GHRS) guidelines emphasize that bone age assessment via left-hand X-ray is essential before initiating GH therapy and should guide expected treatment duration. A girl with a bone age of 13 years may have very little time left to respond, even if her chronological age is younger.

Menstrual Cycle Effects

Once a girl with treated GHD reaches reproductive age, GH and IGF-1 fluctuate across the menstrual cycle. In reproductively normal women, IGF-1 tends to be slightly lower during the luteal phase. This has not been studied prospectively in sermorelin-treated adolescents transitioning to adulthood, which is a genuine evidence gap that the clinical community has not addressed.

What Clinicians Actually Prescribe: Dosing in Practice

Pediatric endocrinologists who use sermorelin for GHD typically follow a weight-based dosing framework adapted from the original Geref prescribing information and from the GHRH stimulation test literature, modified for compounded product. No current FDA-approved label exists, so the following represents observed clinical practice, not a package insert.

Standard Pediatric Dosing Approach

| Parameter | Typical Practice | |---|---| | Dose | 0.2 to 0.3 mcg/kg/day subcutaneous | | Timing | Nightly at bedtime (aligns with endogenous GH peak) | | Injection site | Abdomen, thigh, or upper arm; rotate sites | | Monitoring interval | Every 3 to 6 months for IGF-1, growth velocity, bone age | | Target IGF-1 | Age- and sex-normalized reference range (mid-normal) | | Duration | Until adequate height velocity achieved, growth plates approaching fusion, or response plateau |

The bedtime dosing is not arbitrary. Endogenous GH secretion peaks during slow-wave sleep. Administering sermorelin at bedtime synchronizes the drug's stimulatory effect with the body's natural GH pulse window, maximizing pituitary responsiveness.

Some compounding pharmacies provide sermorelin in pre-filled syringes or lyophilized powder requiring reconstitution. The reconstituted product is typically stored refrigerated and used within 28 to 30 days. Parents administering injections at home need specific training on reconstitution and injection technique, and this is a practical barrier that clinicians must address at the outset.

Monitoring IGF-1: What the Numbers Mean in Girls

Insulin-like growth factor 1 (IGF-1) is the primary biomarker used to monitor GH therapy response. Reference ranges for IGF-1 are sex- and age-specific, and girls have modestly different normative values than boys at the same Tanner stage. A girl whose IGF-1 is at the 50th percentile for her sex and bone age is considered adequately treated. Over-suppression of IGF-1 above the upper reference limit raises concern for excess GH exposure and is a reason to reduce dose.

The Endocrine Society's 2016 clinical practice guideline on GH deficiency in children recommends monitoring IGF-1 every 3 to 6 months during treatment and adjusting dose to maintain IGF-1 within the normal age- and sex-matched reference range. Although that guideline addresses rhGH primarily, most clinicians apply the same monitoring framework to sermorelin because the downstream biomarker, IGF-1, is the same regardless of which stimulus triggered GH release.

Side Effects and Safety Profile

Sermorelin's safety profile in pediatric populations is generally considered favorable, partly because it works through native pituitary regulation rather than delivering supraphysiologic doses of GH.

Common Side Effects

• Local injection site reactions: redness, swelling, or itching at the injection site, reported in up to 17 percent of patients in pre-approval trials
• Flushing and warmth, typically brief and within minutes of injection
• Headache, usually mild and self-limiting
• Drowsiness (expected given bedtime dosing)

Uncommon but Monitored Concerns

• Hypothyroidism: GH therapy, including sermorelin, can unmask subclinical hypothyroidism by accelerating T4 to reverse T3 conversion. Thyroid function should be checked before starting and periodically during treatment. Girls with Turner syndrome or autoimmune thyroid risk are particularly vulnerable.
• Scoliosis progression: Rapid growth from any GH stimulus can worsen pre-existing scoliosis. Spine screening is standard in girls receiving GH therapy.
• Slipped capital femoral epiphysis (SCFE): Rare, but GH therapy is a recognized risk factor. Hip or knee pain during treatment warrants urgent orthopedic evaluation.
• Elevated intracranial pressure: Papilledema and headache should prompt ophthalmologic evaluation. Rare but documented with GH axis stimulation.

What We Do Not Know

Compounded sermorelin has not been subjected to the same post-marketing surveillance as approved rhGH products. Impurities in poorly manufactured compounded peptides are a real concern. The FDA has issued warnings about compounded peptides that do not meet sterility and potency standards. Families should verify that any compounding pharmacy holds current 503A accreditation and is subject to state board of pharmacy oversight.

Pregnancy, Lactation, and Contraception

Sermorelin is contraindicated in pregnancy. This section applies to adolescent girls who are sexually active and to young women transitioning off pediatric GHD treatment.

Pregnancy Safety

No adequate human pregnancy safety data exist for sermorelin. Animal reproduction studies were not designed to establish human risk equivalence. Because sermorelin stimulates the GH axis, and because GH and IGF-1 have established roles in fetal and placental growth, there is a plausible biological concern about disruption of normal gestational physiology, though the magnitude of risk in humans is unknown.

The FDA's Drugs@FDA database lists sermorelin as Pregnancy Category C under the old classification system, meaning animal studies showed adverse effects and no adequate human data existed. Under the current Pregnancy and Lactation Labeling Rule (PLLR), the original prescribing information did not receive an updated label because the product was withdrawn before PLLR took effect. Clinicians should treat sermorelin as contraindicated in pregnancy until human safety data exist.

Any sexually active adolescent girl receiving sermorelin should use reliable contraception. This is a direct clinical instruction, not a soft recommendation.

Lactation

No human data on sermorelin transfer into breast milk exist. The molecular weight of sermorelin (approximately 3,357 Da) suggests it would likely be present in breast milk, but oral bioavailability of peptides is negligible, which may limit infant exposure. The absence of data means sermorelin should not be used in lactating women unless the prescribing clinician has weighed the specific clinical need and documented this discussion.

Transition-Age Girls: Contraception and Family Planning

Girls treated for GHD through adolescence will eventually discuss stopping or transitioning therapy at growth plate fusion. If a young woman plans pregnancy in the near future, she should stop sermorelin and allow adequate washout. Endogenous GHRH has a half-life of minutes; compounded sermorelin's pharmacologic effect on IGF-1 normalizes within days to weeks of stopping. A 4-week washout before attempting conception is a reasonable precaution, though no specific clinical trial defines this interval.

Who This Is Right For and Who Should Not Use It

Life Stages and Conditions Where Sermorelin for GHD May Be Considered

• Prepubertal girls (Tanner stage 1 to 2) with confirmed GHD by two stimulation tests and open growth plates. This is the strongest candidate group.
• Early pubertal girls (Tanner stage 2 to 3) with bone age showing at least 2 to 3 years of growth remaining. Estrogen priming may improve pituitary responsiveness.
• Girls with Turner syndrome receiving estrogen replacement, where GHD co-occurs. Note: Turner syndrome girls are often short for reasons beyond GHD, and rhGH at higher doses is the more established approach. Sermorelin has not been specifically studied in Turner syndrome.
• Girls with PCOS and concurrent GHD: PCOS is associated with altered GH pulsatility and IGF-1 levels. There is no dedicated trial of sermorelin in girls with PCOS and GHD, so clinicians treating this overlap must monitor carefully and document rationale.

Who Should Not Use Sermorelin for GHD

• Girls with closed or near-closed growth plates (bone age greater than 14 to 15 years in most girls). Height benefit is minimal or zero.
• Girls with active malignancy or history of intracranial tumor causing GHD, where GH axis stimulation may be contraindicated pending oncology clearance.
• Girls with pituitary destruction (e.g., panhypopituitarism from radiation or surgical damage) where the pituitary has insufficient functional somatotrophs to respond to sermorelin. These patients need rhGH, not a pituitary stimulant.
• Pregnant adolescents: contraindicated as noted above.
• Girls with known hypersensitivity to sermorelin or any component of the compounded formulation.

Sermorelin vs. RhGH: A Practical Comparison for Girls and Their Families

The decision between sermorelin and rhGH in pediatric GHD is genuinely complex. No randomized controlled trial has compared the two directly in girls as a primary endpoint. The comparison below draws on published observational data and clinical experience.

| Feature | Sermorelin | rhGH | |---|---|---| | Mechanism | Stimulates pituitary GH release | Replaces GH directly | | FDA status for pediatric GHD | Off-label (withdrawn 2008) | Multiple FDA-approved products | | Pulsatile GH preservation | Yes | No | | Efficacy data in girls | Limited, male-predominant trials | Extensive, including girls | | Annual cost (approximate) | Lower (compounding) | $10,000 to $60,000+ | | Insurance coverage | Rarely covered (off-label compounded) | Usually covered with prior auth | | Monitoring | IGF-1, growth velocity, bone age | Same | | Pregnancy contraindication | Yes | Yes (rhGH also contraindicated) |

A 2020 review in the Journal of Clinical Endocrinology and Metabolism noted that GHRH analogs remain clinically used in countries where rhGH access is limited by cost, supporting the role of sermorelin as a pragmatic alternative in cost-constrained settings.

What the Endocrine Society and GHRS Guidelines Actually Say

The 2016 Endocrine Society Clinical Practice Guideline on Growth Hormone Deficiency in Children does not endorse sermorelin as a primary treatment. It recommends rhGH as the standard of care. The guideline states: "We recommend treating growth hormone-deficient children with GH to normalize height during childhood and achieve a normal adult height."

The Growth Hormone Research Society consensus 2019 position similarly does not list sermorelin among preferred agents, reflecting the absence of a current branded product and the dominance of rhGH in the evidence base.

Clinicians prescribing sermorelin for pediatric GHD are therefore operating outside current major guideline recommendations. That does not make the practice wrong, but it does require documented informed consent explaining the off-label status, the cost-benefit reasoning, and the monitoring plan.

"The most important principle in treating a child with GHD is that treatment should be individualized based on the severity of deficiency, growth potential remaining, and family circumstances," noted in a 2019 GHRS workshop summary on GH therapy access. The workshop report is available through the Journal of Clinical Endocrinology and Metabolism.

Informed Consent: What a Family Must Understand Before Starting

For any off-label compounded drug in a child, informed consent is not a formality. These are the specific points a clinician must cover:

1. Sermorelin is not FDA-approved for pediatric GHD and has not been since 2008.
2. The compounded product has no standardized quality guarantees equivalent to an FDA-approved drug.
3. Insurance is unlikely to cover the cost; the family will likely pay out of pocket.
4. RhGH is the guideline-recommended alternative and has a stronger evidence base.
5. Response is not guaranteed; some children with partial pituitary insufficiency may not respond because the pituitary cannot generate adequate somatotrophs to respond to GHRH stimulation.
6. Monitoring every 3 to 6 months is mandatory, not optional.
7. If the child reaches sexual activity, contraception is required during treatment.
8. The treatment window in girls closes earlier than in boys because of earlier growth plate fusion.

A Note on PCOS, Thyroid, and Overlapping Conditions in Adolescent Girls

Girls presenting for evaluation of short stature and possible GHD frequently have other diagnoses that affect the clinical picture.

PCOS: Hyperinsulinism in PCOS can suppress SHBG and alter IGF-1 interpretation. An elevated IGF-1 in a girl with PCOS and GHD may reflect insulin-driven IGF-1 production rather than adequate GH response. Clinicians must interpret IGF-1 in the context of insulin sensitivity markers. Research in the Journal of Clinical Endocrinology and Metabolism documented altered GH pulsatility in adolescents with PCOS, which complicates GHD stimulation testing.

Autoimmune thyroid disease: Hashimoto thyroiditis is common in adolescent girls. Untreated hypothyroidism suppresses GH secretion independently, meaning a girl with undiagnosed thyroid disease may appear to have GHD on stimulation testing when the real problem is thyroid deficiency. Thyroid function must be normalized before GHD testing is considered valid. The Endocrine Society guideline explicitly recommends this.

Celiac disease: Undiagnosed celiac disease causes short stature and mimics GHD. A tissue transglutaminase IgA test is standard in the workup of a short girl before attributing the diagnosis to GHD.

Girls with Turner syndrome have a distinct growth trajectory governed by the absence of one X chromosome's contribution to growth gene dosage and require specialized growth management protocols that differ substantially from idiopathic GHD management.